Study: CBT After Ketamine Cuts Depression Relapse Risk

What the CBT-ENDURE Trial Found

A randomized controlled trial published in May 2026 in the Journal of Clinical Psychiatry has added the strongest evidence yet that ketamine works best as a launching pad — not a finish line. The CBT-ENDURE trial enrolled adults with major depressive disorder (MDD) and active suicidal ideation who had already received esketamine (Spravato) nasal spray. Participants were then randomized into two groups: one continued esketamine alone, the other added a structured 16-week course of cognitive behavioral therapy (CBT).

The findings were clear. Patients in the combined CBT-plus-esketamine group showed meaningfully greater reductions in both suicidal ideation and overall depression severity compared to those on esketamine alone. The effect held across the duration of the trial, suggesting the benefit wasn't just a short-term boost but a durable shift in how patients managed their symptoms. The trial's name — ENDURE — reflects exactly that intent: sustaining gains over time, not just achieving an initial response.

This is a significant contribution to the literature. While clinicians have long suspected that pairing ketamine with psychotherapy improves outcomes, randomized evidence has been relatively thin. CBT-ENDURE changes that.

Why This Applies to Oral Ketamine Tablets, Too

The trial used esketamine, the S-enantiomer of ketamine delivered intranasally and FDA-approved under the brand name Spravato. But the core insight — that structured psychotherapy amplifies and prolongs ketamine's antidepressant effects — almost certainly extends to oral ketamine tablets, which are the form many patients access through telehealth programs and at-home treatment protocols.

Here's the mechanism behind that reasoning: both esketamine and racemic oral ketamine work primarily through NMDA receptor antagonism, producing a rapid shift in mood and a transient state of heightened neuroplasticity. In that window, the brain is thought to be more receptive to forming new cognitive patterns — exactly what CBT is designed to install. The difference between the two formulations is largely pharmacokinetic. Oral tablets have lower bioavailability, typically 20–30%, compared to roughly 45% for nasal absorption, and their onset is slower and more gradual. But the downstream effect on mood, motivation, and cognitive flexibility is mechanistically similar, which is why clinicians across the ketamine space — IV infusion centers, compounding pharmacies, and telehealth tablet programs alike — have moved toward recommending therapy integration as a standard of care.

CBT-ENDURE gives that recommendation its most rigorous backing to date. If the therapy-plus-ketamine combination outperforms ketamine alone in a controlled trial using a nasal formulation, the burden of proof now falls on programs that don't integrate therapy to explain why they're leaving outcomes on the table.

The Neuroplasticity Window: Timing Your Therapy Around Dosing

One practical dimension that CBT-ENDURE reinforces is the concept of the post-ketamine neuroplasticity window — the period, generally estimated at 24 to 72 hours after a dose, when ketamine's effects on synaptic growth and cognitive flexibility are thought to be most pronounced. Many ketamine providers already advise patients to schedule therapy appointments within this window, and the CBT-ENDURE protocol — which ran therapy sessions alongside ongoing esketamine treatment — supports the idea that sustained, repeated engagement during these windows drives cumulative benefit.

For oral ketamine tablet users, this has a direct scheduling implication. Unlike IV infusions, which are clinic-based and can be naturally paired with in-clinic therapy, tablets are typically taken at home. That flexibility is one of their key advantages, but it also requires intentional structuring. Patients who take a dose on a Tuesday evening may benefit most from a therapy session Wednesday or Thursday — not the following week when the neuroplasticity signal has faded. Discussing this timing with both your ketamine prescriber and your therapist is worth the conversation.

It's also worth noting that the CBT protocol in CBT-ENDURE ran for 16 weeks — not just a session or two. This underscores that the benefit comes from building cognitive skills over time, using each post-ketamine window as an opportunity to practice and reinforce new thought patterns. Brief, one-time therapy pairings likely don't capture the full effect.

What Oral Ketamine Patients Should Do With This Information

The CBT-ENDURE findings carry several practical messages for anyone using oral ketamine tablets as part of a depression treatment plan:

• Treat therapy as part of the protocol, not an add-on. If your prescriber or telehealth platform hasn't discussed therapy integration, bring up this trial. The data now supports therapy as a clinical necessity for durable outcomes, particularly for patients with significant depression or suicidal ideation.
• Ask about timing. Work with your care team to schedule therapy appointments within the 24–72-hour post-dose window when possible. This isn't always logistically easy, but even approximate alignment is likely better than random scheduling.
• Think long-term. The 16-week CBT course in CBT-ENDURE wasn't designed to treat the acute episode — it was designed to prevent the next one. Patients who are tapering dosing frequency or planning to discontinue ketamine tablets should prioritize having active therapeutic support during that transition.
• High-acuity patients deserve both tools. The trial specifically enrolled patients with suicidal ideation. Oral ketamine programs treating this population should treat therapy access as essential, not optional. If you or someone you know is in this category, the combination approach now has direct trial-level support.

The field of ketamine medicine has always understood that the molecule opens a door. CBT-ENDURE is the clearest evidence yet of what happens when patients have the skills — and the support — to walk through it.